Breaking Down Spire Healthcare Group plc Financial Health: Key Insights for Investors

Investors scrutinising Spire Healthcare Group plc (SPI.L) will find a mix of momentum and caution in the numbers: Group revenue in FY2024 rose by 11.2% to £1,511.2m (Hospitals contributing £1,390m, up 5.5%), Primary Care revenue grew 15% to £121m pro forma, while Hospitals adjusted EBITDA climbed 11.1% to £260.0m with an 18.0% margin; operating profit reached £137.5m (+9%), adjusted PBT jumped 29% to £50m, yet net profit margin sits at a modest 1.68% and first-half 2025 adjusted EBITDA was £133.8m (16.8% margin); balance sheet and liquidity show £365m of borrowings (debt-to-equity ~1.71), cash of £41.2m, a current ratio of 0.70 and access to undrawn facilities and extended lending to August 2028, while market capitalisation is ~£747.6m with a P/E of 40.39 and ROE of 3.39%-all against headwinds including £30m of 2025 cost pressures and a decline in Self-Pay admissions-read on for a detailed breakdown of revenue drivers, profitability, leverage, liquidity and valuation implications for shareholders.

Spire Healthcare Group plc (SPI.L) - Revenue Analysis

Spire Healthcare Group plc reported continued top-line expansion in FY2024 and into 2025, driven by hospital services and accelerating Primary Care momentum.

• Group revenue (FY2024): £1,511.2 million (up 11.2% from £1,359.0m in FY2023)
• Hospitals division revenue (FY2024): £1,390 million (up 5.5% year-on-year)
• Primary Care revenue (pro forma): £121 million (up 15%)
• Hospitals adjusted EBITDA (FY2024): £260.0 million; adjusted EBITDA margin: 18.0%
• FY2025 guidance: mid-single-digit percentage revenue growth; adjusted EBITDA: £270-£285 million
• Recent trading: revenue up 4.9% in H1 2025 and up 3.6% year-on-year in July-October 2025

Key operational drivers include higher elective activity in hospitals, expansion and scaling of Primary Care services, and cost leverage improving adjusted EBITDA. For corporate strategy and long-term positioning, see Mission Statement, Vision, & Core Values (2026) of Spire Healthcare Group plc.

Spire Healthcare Group plc (SPI.L) Profitability Metrics

• Operating profit (FY2024): £137.5m, up 9% from £126.2m (FY2023).
• Adjusted profit before tax (FY2024): £50.0m, up 29% year-on-year.
• Hospitals adjusted EBITDA margin (FY2024): 18.0%, an improvement of 0.4 ppt.
• Net profit margin (FY2024): 1.68%, indicating limited bottom‑line conversion.
• FY2025 guidance: adjusted EBITDA expected at the lower end of £270m-£285m.
• H1 2025 adjusted EBITDA: £133.8m with a margin of 16.8% (slightly down on prior year).

• Margin expansion in Hospitals (↑0.4ppt) shows efficiency gains on core services, supporting sustainable adjusted EBITDA improvement.
• Adjusted PBT growth (29%) suggests better underlying profitability after one‑offs and adjustments, but net margin remains thin at 1.68%.
• FY2025 guidance anchored at the lower end of £270-£285m signals management conservatism given near‑term demand and cost pressures.
• H1 2025 performance (£133.8m, 16.8% margin) indicates a slight margin compression versus prior periods-monitor H2 mix and cost control.

Spire Healthcare Group plc (SPI.L) Debt vs. Equity Structure

• Total borrowings as at 31 December 2024: £365.0m.
• Breakdown: £325.0m Senior Loan Facility; £40.0m drawn Revolving Credit Facility (RCF).
• Undrawn RCF capacity: £60.0m.
• Reported debt-to-equity ratio: ~1.71, reflecting substantial leverage.

• Extension: Senior loan facility and RCF extended by one year to Feb 2027 (agreement date 3 Mar 2023).
• Covenants: Financial covenants are materially unchanged from prior terms.
• Liquidity buffer: £60.0m undrawn RCF provides short-term flexibility versus drawn borrowings of £40.0m.

• Leverage profile (debt-to-equity ~1.71) indicates higher sensitivity to earnings volatility and interest cost movements.
• Access to undrawn RCF and extended facility maturity reduce near-term refinancing risk, subject to covenant compliance.
• Going concern assessment through 30 Jun 2026 signals management confidence in short-to-medium term solvency, but covenants and operational performance remain key monitoring points.

Spire Healthcare Group plc (SPI.L) - Liquidity and Solvency

Key liquidity and solvency indicators for Spire Healthcare Group plc (SPI.L) point to a mixed profile: constrained near-term liquid resources but reinforced by extended lending facilities and substantial fixed-asset backing.

• Cash on hand (31 Dec 2024): £41.2 million.
• Current ratio: 0.70, indicating current liabilities exceed current assets and suggesting potential short-term liquidity pressure.
• Lending facilities: £425 million facility extended to August 2028, improving available financing runway.
• FY2025 adjusted EBITDA guidance: company expects adjusted EBITDA at the lower end of the £270m-£285m range.
• Freehold property portfolio valuation: >£1.4 billion, a material asset base supporting solvency metrics.
• Going concern assessment: company has assessed going concern through to 30 June 2026.

Practical considerations for investors include the reliance on operating cash generation (adjusted EBITDA) to service obligations, the mitigating effect of the extended £425m facility, and the balance-sheet strength provided by a >£1.4bn freehold estate. For additional corporate context and history, see: Spire Healthcare Group plc: History, Ownership, Mission, How It Works & Makes Money

Spire Healthcare Group plc (SPI.L) - Valuation Analysis

Spire Healthcare Group plc (SPI.L) currently shows a market capitalization of approximately £747.6 million and a price-to-earnings (P/E) ratio of 40.39, indicating a relatively high valuation versus current earnings. The reported return on equity (ROE) stands at 3.39%, reflecting efficient use of equity in the company's context. The balance sheet is supported by a substantial freehold property portfolio valued at over £1.4 billion, which underpins asset-backed valuation. Management expects adjusted EBITDA for FY2025 to sit at the lower end of the £270 million-£285 million guidance range, while debt maturities are mitigated by the extension of £425 million lending facilities to August 2028.

• Market capitalization: ~£747.6 million
• P/E ratio: 40.39
• ROE: 3.39%
• Freehold property portfolio: >£1.4 billion
• FY2025 adjusted EBITDA guidance: lower end of £270m-£285m
• Lending facilities: £425m extended to Aug 2028

For broader context on the company's background and business model see: Spire Healthcare Group plc: History, Ownership, Mission, How It Works & Makes Money

Spire Healthcare Group plc (SPI.L) - Risk Factors

Key near‑term and structural risks for Spire Healthcare Group plc (SPI.L) that investors should weigh alongside operational performance.

• 2025 cost headwinds: a confirmed incremental cost pressure of approximately £30.0m driven by national insurance increases, minimum wage uplifts and higher energy costs.
• Decline in Self‑Pay admissions: year‑on‑year decline that accelerated in H2, reducing higher‑margin revenue from private patients and compressing overall margins.
• NHS mix pressure in H2: a shift toward NHS work in the second half reduced average realised margins as capacity and pricing dynamics adjusted to higher NHS demand.
• External environment volatility: changing payor mix (NHS vs Self‑Pay), and the planned end of the group's energy hedge expose earnings to commodity and contract pricing swings.
• Leverage and liquidity: a debt‑to‑equity ratio of ~1.71 indicating substantial leverage; a current ratio of 0.70 signalling potential short‑term liquidity constraints.

Practical investor considerations:

• Profitability sensitivity: with higher fixed labour and energy costs, breakeven levels for private versus NHS case mix change materially.
• Cash flow and refinancing risk: leverage near 1.7x equity and a sub‑1 current ratio increase susceptibility to interest, covenant and working capital stress.
• Revenue concentration risk: accelerated Self‑Pay decline heightens dependence on NHS income, which typically yields lower margins and different payment timings.
• Hedge and commodity exposure: expiration of the energy hedge could add volatility to operating costs unless replaced or mitigated.
• Monitoring signals: watch quarterly Self‑Pay admissions, NHS share of admissions, gross margin % and liquidity metrics (cash, available facilities).

For broader investor context and shareholder composition, see: Exploring Spire Healthcare Group plc Investor Profile: Who's Buying and Why?

Spire Healthcare Group plc (SPI.L) - Growth Opportunities

Spire Healthcare Group plc (SPI.L) presents a mix of growth catalysts and financial considerations that investors should weigh. The company's operational outlook, balance sheet composition and asset base create pathways for expansion, while certain liquidity and leverage metrics suggest areas to monitor closely.

• FY2025 revenue guidance: mid-single-digit percentage growth anticipated.
• Adjusted EBITDA guidance for FY2025: projected between £270.0m and £285.0m.
• Freehold property portfolio valuation: >£1.4 billion - strategic asset for capacity expansion, redevelopment or sale-and-leaseback transactions.
• Lending facilities: £425.0m extended to August 2028, improving funding visibility for capex and M&A.
• Going concern: assessed through 30 June 2026, indicating management confidence in short-to-medium term liquidity and operations.
• Leverage and liquidity signals: debt-to-equity ~1.71 (substantial leverage); current ratio 0.70 (potential near-term liquidity constraint).

Key tactical levers Spire could deploy to convert these opportunities into value:

• Monetise portions of the freehold estate to fund targeted capex or reduce net debt.
• Use the extended £425m facilities to time acquisitions or fund refurbishment without urgent refinancing.
• Prioritise EBITDA-accretive initiatives (efficiency programs, selective service-line expansion) to improve leverage metrics and cover interest costs.
• Manage working capital tightly to address the low current ratio and avoid liquidity squeezes during cyclical demand shifts.
• Consider balance-sheet optimisation (debt tenor extension, covenant management, potential equity issuance) to de-risk the ~1.71 debt-to-equity position.

For further investor-focused context and positioning of holders, see Exploring Spire Healthcare Group plc Investor Profile: Who's Buying and Why?